Cytek Biosciences to Report Fourth Quarter and Full Year 2021 Financial Results on February 23, 2022

Rhea-AI Summary

Cytek Biosciences (CTKB) will announce its fourth quarter and full year 2021 financial results on February 23, 2022, after market close. A conference call, scheduled for 2:00 p.m. Pacific Time, will discuss the results and future outlook. Cytek is known for its Full Spectrum Profiling™ (FSP™) technology, enhancing cell analysis with high-resolution and sensitivity. The Aurora and Northern Lights systems are central to Cytek’s offerings. Note that most products are for research use only, except for Northern Lights CLC, which is cleared for clinical use in China and the EU.

Positive

• Scheduled announcement of financial results may indicate readiness for transparency and engagement with investors.
• Innovative technology (Full Spectrum Profiling™) positions Cytek favorably in the cell analysis market.

Negative

• Most products are for research use only, limiting market potential in clinical applications.

FREMONT, Calif., Feb. 11, 2022 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), today announced it will report financial results for the fourth quarter and full year 2021 after market close on Wednesday, February 23^rd, 2022. The company’s management will webcast a corresponding conference call beginning at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time to discuss its results, business developments and outlook.

Live audio of the webcast will be available on the “Investors” section of the company website at investors.cytekbio.com

About Cytek Biosciences
Cytek Biosciences is a leading cell analysis solutions company advancing the next generation of cell analysis tools by delivering high-resolution, high-content and high-sensitivity cell analysis utilizing its patented Full Spectrum Profiling™ (FSP™) technology. Cytek’s novel approach harnesses the power of information within the entire spectrum of a fluorescent signal to achieve a higher level of multiplexing with exquisite sensitivity. Cytek’s FSP platform includes its core instruments, the Aurora and Northern Lights™ systems, its cell sorter, the Aurora CS, and reagents, software and services to provide a comprehensive and integrated suite of solutions for its customers. Cytek is headquartered in Fremont, California with offices and distribution channels across the globe.

Other than Cytek’s Northern Lights CLC system, which is available for clinical use in China and the European Union, Cytek’s products are for research use only – not for use in diagnostic procedures or for clinical purposes.

Cytek, Full Spectrum Profiling, FSP and Northern Lights are trademarks or registered trademarks of Cytek Biosciences, Inc.

Investor Relations Contact:
Carrie Mendivil/Alex Khan
Gilmartin Group LLC
investors@cytekbio.com 

Media Contact:
Stephanie Olsen
Lages & Associates
(949) 453-8080
stephanie@lages.com 

FAQ

When will Cytek Biosciences report its financial results for 2021?

Cytek Biosciences will report its financial results for the fourth quarter and full year 2021 on February 23, 2022.

What technology does Cytek Biosciences utilize?

Cytek Biosciences utilizes Full Spectrum Profiling™ (FSP™) technology for high-resolution cell analysis.

What is the significance of the conference call on February 23, 2022?

The conference call will provide insights into Cytek's financial results, business developments, and future outlook.

Is Cytek's Northern Lights product available for clinical use?

Yes, the Northern Lights CLC system is available for clinical use in China and the European Union.

What are the core products offered by Cytek Biosciences?

Cytek's core products include the Aurora and Northern Lights systems along with associated reagents and software.